<DOC>
	<DOCNO>NCT00885937</DOCNO>
	<brief_summary>The study focus prove favorable safety profile new formulation .</brief_summary>
	<brief_title>Comparative Safety Study New Sinecort Formulation Versus Positive Control</brief_title>
	<detailed_description />
	<criteria>Age least 18 year Skin type I , II , III accord Fitzpatrick Subjects childbearing potential must use acceptable method contraception . Hormonal oral contraceptive drug , intrauterine device ( IUD ) abstinence consider acceptable method contraception . Clinical history suggestive intolerance , allergies idiosyncrasy one product ingredients product include patch . Known skin allergy . Dermatologic disease might interfere evaluation test site reaction . Other ( ) , consider important investigator ( e.g . multiple birth mark test area , important hair growth test area , pigment extremely suntanned skin impair visual assessment , tattoos test area . Topical use cosmetic preparation test area within 5 day prior Day 1 ( Start Treatment ) trial Within 3 week prior Day 1 entire trial . Any systemic topical medication likely interfere trial purpose : e.g . immunemodulating therapy ( e.g . corticosteroid , cytotoxics immunosuppressant ) dermatological medication ( drug medical device . Within 1 week prior Day 1 entire trial medication common effect perfusion skin vessel ( e.g . vasodilator vasoconstrictor , ÃŸreceptor block drug , antihistamine ) use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Dexpanthenol</keyword>
	<keyword>Safety ,</keyword>
	<keyword>New formulation</keyword>
	<keyword>Topical administration</keyword>
</DOC>